Lead and oversee the strategy and implementation of biomarker programs for inflammatory and immune diseases, focusing on clinical and preclinical transitions through Phase 3 trials.
Founded in 2022, Apogee Therapeutics, Inc. (Ticker: APGE) is a well-funded, Nasdaq listed company that offers the opportunity to work in a fast-paced, highly dynamic environment. At Apogee, you can actively contribute to shaping the company culture, take on various roles and responsibilities, and grow professionally.
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of atopic dermatitis (AD), which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of leadership and expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.
We are a fast-paced company committed to building an exceptional culture, founded on our C.O.R.E. values: Caring, Original, Resilient and Egoless and a commitment to refusing to stop at “good enough”.
If this sounds like you, keep reading!
We are seeking a highly experienced and motivated individual to lead our biomarker efforts in the field of inflammatory and immune diseases, with a focus on atopic dermatitis, asthma, COPD and EOE. Reporting to the Senior Vice President – Research and Translational Medicine, the successful candidate will be responsible for overseeing the strategy and implementation of all our translational clinical and preclinical biomarker programs from early but particularly late-stage development including Phase 3 trials and BLA-readiness for all our assets. As Vice President – Inflammatory and Immune Disease Biomarker Development you will be leading and growing our internal team as well as our network of external vendors and collaborators.
If you are a driven and innovative senior leader with a passion for biomarker development in I&I diseases as well as a deep late-stage clinical development understanding, we encourage you to apply for this exciting opportunity to make a meaningful impact on the lives of patients.
Key Responsibilities
Ideal Candidate
The anticipated salary range for candidates for this role will be $320,000-$355,000 per year. The final salary offered will depend on several factors, which may include, but is not limited to relevant years of experience, educational background, and geography.
Paid Time Off
We provide competitive time off, including three weeks PTO, two one-week company-wide shutdowns a year and dedicated paid sick leave
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics designed to deliver differentiated efficacy and dosing in the expansive immune and inflammatory (I&I) markets. We cater to patients and healthcare providers seeking innovative treatment options that can address unmet medical needs.
Please mention you found this job on AI Jobs. It helps us get more startups to hire on our site. Thanks and good luck!